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Development of the nervous system proceeds through a set of complex checkpoints which
arise from a combination of sequential gene expression and early neural activity sculpted by
the environment. Genetic and environmental insults lead to neurodevelopmental disorders
which encompass a large group of diseases that result from anatomical and physiolog-
ical abnormalities during maturation and development of brain circuits. Rett syndrome
(RTT) is a neurological disorder of genetic origin, caused by mutations in the X-linked gene
methyl-CpGbinding protein 2 (MeCP2). It features a range of neuropsychiatric abnormalities
including motor dysfunctions and mild to severe cognitive impairment. Here, we discuss
key questions and recent studies describing animal models, cell-type speciﬁc functions of
methyl-CpG binding protein 2 (MeCP2), defects in neural circuit plasticity, and attempts to
evaluate possible therapeutic strategies for RTT.We also discuss how genes, proteins, and
overlapping signaling pathways affect the molecular etiology of apparently unrelated neu-
ropsychiatric disorders, an understanding of which can offer novel therapeutic strategies
for a range of autism spectrum disorders (ASDs).
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INTRODUCTION
Rett syndrome (RTT) [Online Mendelian Inheritance in Man
(OMIM) #312750], ﬁrst reported by the Austrian physician
Andreas Rett, is a monogenic, postnatal developmental disorder
that affects normal brain development during early childhood in
females, with an incidence of 1 in 10,000–15,000 live births (Rett,
1966; Chahrour and Zoghbi, 2007). Patients with RTT appear to
reach developmental milestones seemingly normally until about
6–18months after birth when signs and symptoms of the disease
begin to appear. This typically includes severe mental retarda-
tion, stereotypic hand movements, motor coordination deﬁcits,
epileptic seizures, language and learning disabilities, and mild to
severe cognitive impairments (Hagberg et al., 1983;Nomura, 2005;
Chahrour and Zoghbi, 2007). Other clinical hallmarks include
ataxia, spasticity, respiratory abnormalities, and autonomic dys-
function (Williamson andChristodoulou,2006). Loss-of-function
mutations in the MECP2, which encodes a transcriptional regu-
lator and epigenetic modiﬁer MeCP2, have been found to be the
primary genetic component in 90%of patients suffering fromRTT
(Lewis et al., 1992; Amir et al., 1999; Guy et al., 2011). Interest-
ingly, only one copy of MECP2 is active in females due to random
X-chromosome inactivation (Adler et al., 1995). RTT is not a heri-
table disorder andmostmutations inMECP2 arise de novo in germ
cells,usually on thepaternal side (Trappe et al.,2001).Growing evi-
dence implicates alteration of MECP2 expression in the etiology
of several other neuropsychiatric disorders including Angelman
syndrome, childhood schizophrenia, and congenital encephalopa-
thy in boys (Schule et al., 2008). Originally, RTT was considered to
be a disorder of early postnatal life; however, one recent study has
shown that inducible deletionofMECP2 in adults recapitulates the
germ-line knock out phenotype in mice (McGraw et al., 2011).
The link between MECP2 and RTT is fascinating because RTT
is one of a small group of ASDs that gives us the opportunity to
study mutations in a single gene and how they affect sequential
phenotypic checkpoints of brain development leading to neu-
ropathological endpoints in psychiatric disorders (Ben-Ari and
Spitzer, 2010). In this review, we will ﬁrst brieﬂy discuss RTT and
its genetic basis and the role of MeCP2 in brain development
and plasticity. Second, we will provide a detailed description of
mouse models of RTT and discuss their use to study molecular,
synaptic, and circuit pathophysiology and to test novel therapeu-
tic approaches to reverse neurological deﬁcits. Finally, we will
examine how overlapping signaling pathways affect the molecular
etiology of apparently unrelated neuropsychiatric disorders like
Fragile-X syndrome (FXS) and tuberous sclerosis (TSC) and how
such an understanding can be utilized to design novel therapeutic
strategies.
MECP2: MULTI-FUNCTIONAL GLOBAL REGULATOR WITH A
LOCAL FUNCTION?
ThehumanMECP2 gene consists of four exons resulting in expres-
sion of two protein isoforms due to alternative splicing of exon 2.
These splice variants differ only in their N-termini, and include
the more abundant MeCP2-e1 isoform (encoded by MECP2B or
Mecp2α in mice) as well as the MeCP2-e2 isoform (encoded by
MECP2A or Mecp2β in mice; Mnatzakanian et al., 2004; Kriau-
cionis et al., 2006). Gene expression studies show that different
brain regions are enriched with different splice variants; MeCP2-
e2 is prevalent in dorsal thalamus and layer 5 of the cortex while
MeCP2-e1 is detected in the hypothalamus (Dragich et al., 2007).
Recent results suggest that MeCP2-e2 isoform is upregulated in
Aβ-treated cortical neurons and promotes neuronal death in post-
mitotic neurons,a pathwaynormally inhibitedby forkheadprotein
FOXG1 (Dastidar et al., 2012). Furthermore, MECP2 has a long
conserved 3′UTR which contains multiple poly-adenylation sites,
which can additionally generate four different transcripts.
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MeCP2 is a highly conserved basic nuclear protein, initially
found to be associated with methylated DNA (5′ CpG islands)
regulating gene silencing and chromatin remodeling (Nan et al.,
1993; Hendrich and Bird, 1998). MeCP2 is also an “intrinsi-
cally disordered” protein with long stretches of unorganized seg-
ments, without standard three-dimensional secondary structure,
proposed to participate in the formation of a ﬂexible scaffold
required for multiple biological interactions (Adkins and Georgel,
2011). The genome-wide distribution ofMeCP2 has consequences
for global epigenetic state. While MeCP2 is expressed in var-
ious tissues throughout the body, including lung and spleen,
it is abundant in mature, post-mitotic neurons in the adult
brain. Expression of neuronal MeCP2 in mice is developmen-
tally regulated. Initially, MeCP2 expression is high during embry-
onic development, with a low level at birth during neuronal
maturation and synaptogenesis. This is followed by a consis-
tent increase over the ﬁrst three postnatal weeks reaching a
plateau with a subsequent increase later in adult life (Shahbaz-
ian et al., 2002b; Kishi and Macklis, 2004). The role of MeCP2
in the development and maturation of the nervous system com-
pared to the maintenance of adult neurons is not yet fully
understood.
Structurally, MeCP2 is known to have two important func-
tional domains: methyl-CpG binding domain (MBD) and the
transcriptional repressor domain (TRD; Nan et al., 1993, 1997).
There is also an additional C-terminal nuclear localization signal
(NLS) which helps trafﬁc the protein into the nucleus. One way
to analyze MeCP2 function is to identify partner proteins which
interact with these deﬁned protein structural domains. The MBD
speciﬁcally binds to methylated CpG di-nucleotides in DNA and
also to unmethylated four-way DNA junctions suggesting a role
for MeCP2 in regulating higher-order chromatin structure (Gal-
vao and Thomas, 2005). The TRD is involved in transcriptional
repression via the recruitment of transcriptional co-repressors
and chromatin remodeling proteins. MeCP2’s role as transcrip-
tional repressor has been suggested based on the observation
that MeCP2 speciﬁcally inhibits transcription from methylated
promoters (Nan et al., 1997) while TRD recruits co-repressors
like SIN3A and histone deacetylases (HDACs) 1 and 2 causing
global compaction of chromatin by promoting nucleosome clus-
tering. There is also evidence that MeCP2 through its TRD binds
to Y-box binding protein-1 (YB1), a protein implicated in tran-
scriptional activation regulation of splicing in reporter constructs
(Young et al., 2005). Although precise protein–protein interac-
tion mechanisms and consequences are yet unknown, it is clear
that MeCP2 plays an important role in globally regulating chro-
matin structure and transcription of its immediate downstream
targets. The abundance of MeCP2 and its binding sites in the
brain makes it an unlikely candidate to be a gene-speciﬁc classical
transcriptional regulator. It is possible that speciﬁcity of MeCP2
function can be signiﬁcantly controlled post-translationally in a
cell-type speciﬁc manner (Cohen et al., 2011). Our knowledge
of the set of neuronal MeCP2 target genes is incomplete, how-
ever, such knowledge would be of great beneﬁt in determining
the molecular basis of pathology and for potential therapeutic
measures.
MOUSE MODELS FOR RTT
To understand the detailed mechanism of RTT, several animal
models have been generated (Calfa et al., 2011b). MeCP2 null
and conditional mutant mouse models with cell-type or area-
speciﬁc loss of MeCP2 in the brain show phenotypic features
that resemble some features of RTT patient symptoms. All these
models have been generated by mutating the mouse endogenous
Mecp2 gene or by the introduction of the human MECP2 gene
with a representative RTT mutation (see Table 1). These diverse
approaches have produced mouse lines with gene products that
range from a complete absence of the protein (Guy et al., 2001)
to expression of a truncated but non-functional MeCP2 protein
(Chen et al., 2001; Shahbazian et al., 2002a; Gofﬁn et al., 2012).
In addition, mouse models have been created with germ-line or
conditional deletions upon recombination with different tissue,
cell-type, or developmental stage speciﬁc Cre-lines (Chen et al.,
2001). Behavioral face validity of these mousemodels, or howwell
they recapitulate the usual RTT symptoms, is varied. Several of the
mouse models show symptoms common to those present in RTT
patients such as stereotypies, ataxia, akinesia, and breathing irreg-
ularities. Nevertheless, behavioral phenotypes, speciﬁcally anxiety
and socialization are more heterogeneous across lines (Table 1).
This behavioral heterogeneity can be attributed to variability in
mouse line genetic backgrounds and the levels of expression of
theMeCP2 protein due to the type of mutation. Social choice par-
adigms such as the social approach and social recognition tests
show different results when comparing common inbred strains.
Some strains (C57BL/6J, FVB/NJ, AKR/J) show a high preference
for socializing with new stranger animals, whereas other strains
show low preference or even direct avoidance (A/J, BALB, 129S1).
Similarly the time they spend in the closed arms of the plus-maze
test, ameasurement that positively correlates with the anxiety level
of the animal, is also variable. There seems to be an association
between higher degree of anxiety and reduced social interest so
mouse background has to be taken into account when comparing
behavior phenotypes (Moy et al., 2007, 2008, 2009). Interestingly,
the recent literature has started to address whether different trans-
lation types and levels of MeCP2 lead to variation in the anxiety
and social phenotype: the complete lack of protein might pro-
duce a stronger phenotype with less anxiety-like behavior whereas
a truncated protein could generate mouse lines with increased
stress (Chao and Zoghbi, 2012). Understanding the correlation
between functional interaction of the different Mecp2 transcripts
produced by these models with other anxiety-related genes like
corticotrophin releasing hormone (Crh) will be capital, not only to
explain the mice phenotypic variance but for clinical applicability
(De Filippis et al., 2010; Kerr et al., 2010; Gofﬁn et al., 2012).
RTT AS A DISORDER OF SYNAPTIC AND NEURAL CIRCUIT
MATURATION
In many RTT patients and in mouse models of RTT, MECP2 is
absent in nearly half (female heterozygous) or every cell (male
hemizygous) throughout the body. However, experiments with
targeted brain-speciﬁc deletion ofMecp2 (usingNestin-cKOmice)
showing similar phenotype as that of Mecp2 null in all tissues
support a crucial role for brain-speciﬁc Mecp2 defects in the
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pathogenesis and profound neurological phenotype of RTT (Chen
et al., 2001; Guy et al., 2001). Autopsy studies on post-mortem
human brain shows an overall decrease in the size and reduction
in weight and volume of the brain (Armstrong, 2005). However,
the RTT brains does not show any obvious sign of degeneration,
atrophy, or cell death.
STRUCTURAL CHANGES
Although there is no gross structural change in RTT brain, mouse
models of RTT show delayed neuronal maturation and synapto-
genesis (Fukuda et al., 2005). Several recent studies have shown
functional, morphological, and molecular alterations in different
mouse models of RTT. At the cellular level, neuronal soma size is
reduced in the absence of MeCP2 with increased packing density
(Armstrong, 2005). Synaptic structural andmorphological defects
include reduced dendritic branching, spine density, and reduced
spine morphology (Kishi and Macklis, 2004; Belichenko et al.,
2009). Presynaptically, loss of MeCP2 affects the number of axonal
boutons and axonal arborization in general and their targeting
(Belichenko et al., 2009), which suggests a decrease in the number
of synapses in RTT brains. However, in line with the structural
changes, many subtle alterations in synaptic transmission lead to
the neuronalmaturation defects that impact circuit-level plasticity
in these mouse models of RTT.
EXCITATORY: INHIBITORY SYNAPTIC BALANCE
Analysis of spontaneous miniature excitatory and inhibitory post-
synaptic currents (mEPSCs and mIPSCs respectively) in MeCP2
KO mice indicates a change in the excitatory/inhibitory (E/I) bal-
ance as revealed by increased excitatory and reduced inhibitory
synaptic transmission in the hippocampus and cortex (Dani et al.,
2005; Nelson et al., 2006; Chao et al., 2007), whereas E/I balance
fromMecp2Tg1 (with humanMeCP2 over-expressingmice) shows
the opposite effect (Collins et al., 2004). Whole-cell patch-clamp
recordings from thick-tufted layer 5 pyramidal neurons in pri-
mary somatosensory cortex (S1) show that spontaneous EPSC
and spontaneous action potential ﬁring are reduced inMeCP2 KO
malemice (Tropea et al., 2009). Additionally, quadruple whole-cell
patch-clamp recordings from layer 5 pyramidal neurons of four-
week-old MeCP2 KO mouse slices show that excitatory synaptic
connectivity is also reduced with weakening of individual con-
nections (Dani and Nelson, 2009). The evidence for functional
deﬁcits supported by immunoﬂuorescence staining of PSD95 in
MeCP2 KO mice showing a signiﬁcant reduction in layer 5 neu-
rons in motor cortex (M1; Tropea et al., 2009). On the other hand,
extracellular ﬁeld EPSPs recorded from layer 2/3with evoked stim-
ulation in layer 4 in primary sensory and motor areas are unaf-
fected by the expression of a truncated MeCP2 protein (Moretti
et al., 2006). Lastly, inhibitory synaptic transmission might also be
altered inmousemodels of RTT,as evidence indicates that there are
both pre- and postsynaptic defects of GABAergic neurotransmis-
sion in the brainstem (Medrihan et al., 2008). Developmentally,
MeCP2 deﬁciency might have a distinct developmental effect on
circuit-level function. Initial phases of synaptic development and
pruning are normal at retino-geniculate synapses [from postna-
tal day (P)9–21 in MeCP2 KO mice compared to wild-type (WT)
control], whereas the circuit becomes abnormal and immature in
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a subsequent experience-dependent phase (P27–34; Noutel et al.,
2011).
PLASTICITY DEFECTS
Several studies have shown that long-term potentiation and
depression (LTP and LTD respectively), cellular mechanisms of
long-term synaptic plasticity and learning and memory, are
impaired in MeCP2 KO animals. LTP evoked by theta-burst stim-
ulation in L2/3 of S1 is reduced in magnitude in eight-week-old
MeCP2 KO mice compared to wild-type controls, an impairment
that can be reversed by environmental enrichment (Lonetti et al.,
2010). Also, LTP is impaired in hippocampal Schaffer’s collat-
eral (SC)–CA1 synapses despite basal synaptic transmission being
intact (Asaka et al., 2006). Hippocampal slices from adult MeCP2
KO mice show a clear decrease in the magnitude of EPSP with
high frequency stimulation (HFS) but not with more physiologi-
cal theta-burst stimulation (TBS). Interestingly, these experiments
reveal a decrease only in the maintenance phase and not in the
inductionphases of LTP.Considering that distinct proteinmachin-
ery and signaling pathways are involved in the induction and
maintenance phase of LTP, it is possible that MeCP2 KO animals
have selective impairment in plasticity induction. In contrast to
HFS and TBS, amore physiologically plausible plasticity paradigm
studied between paired L5 cortical pyramidal neurons using spike-
timing-dependent protocols revealed no change in LTP in MeCP2
KO mice (Dani and Nelson, 2009). However, in this case, fewer
synaptically-coupled connections were found in MeCP2 KO mice
and individual connections were weaker. This suggests that loss of
Mecp2 function reduces connectivity of excitatory synapses which
precedes deﬁcits in plasticity (Dani and Nelson, 2009). In sup-
port of this stance, a recent study using in utero injection of short
hairpin RNA to knock down Mecp2 and glutamate uncaging by
laser-scanning photostimulation to map neocortical circuit found
thatMecp2 deﬁciency leads to signiﬁcant reduction of mainly local
excitatory input strength in superﬁcial cortical layers (Wood et al.,
2009).Alongwith LTPdeﬁcits,LTD,on the other hand, is also abol-
ished in SC–CA1 synapses in adultMeCP2KOanimals (>6weeks)
with no obvious changes in 3–5week old KO animals (Asaka et al.,
2006). Furthermore, mouse model (MeCP2308, expressing a trun-
cated form of MeCP2 protein showed similar impairments in
synaptic plasticity with reduced LTP and LTD at SC–CA1 synapses
inmice at 5–6months of age, and exhibits increased basal synaptic
transmission and decreased paired-pulse facilitation (PPF; Shah-
bazian et al., 2002a; Moretti et al., 2006). Conversely, a mouse
model with mild Mecp2 over-expression (MeCP2Tg1) shows an
enhanced LTP with normal basal synaptic transmission (Collins
et al., 2004).
The molecular composition of synaptic NMDA receptor sub-
units showed an interesting trend in these MeCP2 KO animals:
GluN2B-to-GluN2A subunit switching, which regulates the chan-
nel kinetics and biophysical properties of excitatory synapses in
the developing brain, shows a delayed postnatal maturation and
may be responsible for themolecular pathology of synaptic defects
in RTT (Asaka et al., 2006).
Recent evidence points to the hypothesis that the neurological
deﬁcits found in RTT arise from a recoverable failure of synap-
tic and circuit development in the brain (Tropea et al., 2009). A
plausible hypothesis, complementary to that of reduced excitatory
synapse maturation, is that the level or nature of inhibition is
altered in mouse models of RTT, so that cortical circuits persist
in an immature state. Consistent with this hypothesis, it has been
shown that the potential to trigger visual cortical plasticity by clos-
ing one eye persists into adulthood in MeCP2 KO mice, well past
the critical period for such plasticity in wild-type mice (Tropea
et al., 2009).
ROLE OF MeCP2 IN HOMEOSTATIC SYNAPTIC SCALING
Synaptic scaling is a form of homeostatic plasticity in which aver-
age neuronal activity levels are modulated to allow for dynamic
adjust of synaptic strength to promote stability of neuronal cir-
cuits (Turrigiano and Nelson, 2004). Recent evidence shows how
MeCP2 mediates activity-dependent synaptic scaling in rat hip-
pocampal cultures (Qiu et al., 2012). Increase in neuronal activity
upon bicuculline treatment leads to an increased level of MeCP2
expression, which in turn binds to the GluR2 promoter and
recruits a repressor complex to inhibit its expression and availabil-
ity of these molecules at the synapse. Regulating AMPA receptor
GluR2 subunit expression is one direct way tomediate an adaptive
response that regulates synaptic strength and prevents recurrent
circuit excitation.
INHIBITION AND RTT
Epilepsy is often seen in RTT patients and often difﬁcult to treat
(Steffenburg et al., 2001). Since most cases of RTT are caused by
mutations in the MECP2 gene, it is assumed that convulsions are
based on genetic mechanisms, however, balance of excitation and
inhibition is also believed to play a critical role in the progression
of the disease during early development. A new study has looked
at dysfunctions of neuronal and network excitability using a com-
bination of voltage-sensitive dye imaging and electrophysiology
in hippocampal slices from symptomatic Mecp2 mutant animals
(Calfa et al., 2011a). They found that CA1 and CA3 regions of the
hippocampus are highly hyper-excitable and network excitability
inCA3may contribute to the hippocampal dysfunction and limbic
seizures observed in Mecp2 mutant mice and RTT patients.
Whereas the loss of MeCP2 is known to alter excitatory synap-
tic transmission and plasticity (Nelson et al., 2006), little is known
about how MeCP2 regulates the development and plasticity of
inhibitory GABAergic circuits and how they are altered in RTT.
In a recent study, using Viaat-Cre/MeCP2−/y (vesicular inhibitory
amino acid transporter) mouse model, it has been shown that loss
of MeCP2 from a subset of forebrain GABAergic neurons also
recapitulates many features of RTT (Chao et al., 2010). MeCP2-
deﬁcient GABAergic neurons show reduced inhibitory quantal
size, consistent with a presynaptic reduction in glutamic acid
decarboxylase 1 (Gad1) and glutamic acid decarboxylase 2 (Gad2)
levels, and GABA immunoreactivity. However, in this study, the
effect of Mecp2 deletion from particular interneuron subclasses
on inhibitory circuit plasticity in vivo has not been assessed.
GLIA AND RTT
Since its discovery, RTT has been regarded primarily as a neuro-
pathophysiological disorder. This conclusion was mainly based
on the ﬁnding that selective re-expression of Mecp2 in post-
mitotic neurons (using neuron-speciﬁc Tau locus) is sufﬁcient
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to rescue RTT (Luikenhuis et al., 2004). However, recent studies
have shown that MeCP2 in glial cells plays a very important role
in neuropathology of RTT. Unlike previous reports, it is now clear
that MeCP2 is also expressed in astrocytes and in vitro co-culture
studies have shown that MeCP2 null astrocytes can have non-cell-
autonomous effects on both wild-type and MeCP2 null neurons
(Ballas et al., 2009). Interestingly, a recent study has shown that
re-expression of Mecp2, preferentially in astrocytes, signiﬁcantly
improves several of the hallmark mouse behavioral phenotypes of
RTT mice (locomotion, anxiety levels, respiratory abnormalities,
and lifespan) compared to globally null mice (Lioy et al., 2011).
Microglia may also inﬂuence the onset and progression of RTT.
Aberrant microglial activity has been found in mouse models of
RTT. Elevated levels of glutamate, released from microglia, may
cause abnormal stunted dendritic morphology, microtubule dis-
ruption, and damage of postsynaptic glutamatergic components
making microglial glutamate synthesis or release a potential ther-
apeutic target for RTT (Maezawa and Jin, 2010; Derecki et al.,
2012).
MOLECULAR PATHOPHYSIOLOGY OF RTT AND THERAPEUTIC
APPROACHES
Usingmouse geneticmodels of RTT,keymolecular signaling path-
ways that contribute to the deﬁcits in synaptic function andmatu-
ration have been studied. Once identiﬁed, these mouse models
have also been used to experimentally validate possible thera-
peutic avenues using genetic, pharmacological, and behavioral
approaches. So far, threemajor approaches have been investigated:
pharmacological treatment aimed to restore signaling pathway
activity, supplementary diets and reinforcement therapies, and
genetic manipulation that re-establish Mecp2 gene expression.
MOLECULAR PATHOPHYSIOLOGY AND EFFECT ON SIGNALING
PATHWAYS
The speciﬁc role of MeCP2 in transcription and translational con-
trol might vary depending on the different molecules recruited
and protein–protein interactions. This complexity, for example, is
shown in the regulation of one of the most important targets of
MeCP2 in the central nervous system: brain-derived neurotrophic
factor (BDNF). MeCP2 regulates BDNF expression by binding to
promoter IV and repressing its transcription until MeCP2 is phos-
phorylated and released via a neuronal activity-dependent mech-
anism. This mechanism might explain the activity-dependent
increase of BDNF, however it is unclear how it would cause the
lower levels of this growth factor observed in RTT patients and
mouse models when compared with healthy individuals or WT
animals (Chang et al., 2006). A recent study (Abuhatzira et al.,
2007) has suggested that BDNF protein down-regulation may be
mediated by dis-inhibition of complex repressor REST/Co-REST.
The translation of this complex is suppressed in the presence
of MeCP2; in MeCP2 null mice the complex is overexpressed.
The REST/Co-REST complex binds to a position between BDNF
promoters I and II, located upstreamof promoter IV, thereby over-
riding the direct effects of MeCP2 on the downstream promoter.
BDNF is critical for neuronal development, synaptic maturation,
and plasticity through the activation of speciﬁc neurotrophic tyro-
sine kinase receptor type 2 (TrkB), which, in turn, activates signal
transduction pathways such as PLCγ, PI3K/Akt, and MAPK/ERK
that regulate protein synthesis and neural function by activating
PSD95 (Yoshii and Constantine-Paton, 2007). This pathway is of
central importance to the expression and amelioration of the RTT
phenotype. Similarly the PI3K-Akt-PSD95 pathway is known to
drive the up-regulation of PSD95 by insulin (Lee et al., 2005),
and this pathway is also stimulated by IGF-1 (Zheng and Quirion,
2004). Although there is not yet a clear picture of how cellular and
molecular changes in RTT neurons in turn regulate their physi-
ological properties, there is increasing evidence showing that the
molecular signaling pathways and aberrant neuronal protein syn-
thesis at the synapses are a possible explanation for several features
in the pathology of RTT. The regulation of protein synthesis via
the PI3K pathway has been proven to be crucial in synaptic func-
tion,dendrite structure, andplasticity (Jaworski et al., 2005;Kumar
et al., 2005; Cuesto et al., 2011). All of these functions have been
shown to be compromised in RTT (Belichenko et al., 2009; Nou-
tel et al., 2011). Recently, direct evidence has demonstrated the
dysregulation of the entire Akt/mTOR axis in MeCP2 null mice,
giving a molecular theoretical framework for the mechanism of
action of genes regulated by MeCP2, like BDNF (Ricciardi et al.,
2011).
The importance of the PI3K pathway is reﬂected in the num-
ber of therapies designed for RTT that aim to restore its activity
through the direct application or augmented endogenous synthe-
sis of growth factors such as BDNF or IGF-1 (Tropea et al., 2009;
Kline et al., 2010; Lonetti et al., 2010; Castro et al., 2011). These
therapies target the tyrosine kinase receptors and hyper-activation
of their subsequent downstream cascade that will cause increased
protein synthesis that in the end impact synaptic maturation and
function (Yoshii and Constantine-Paton, 2007).
GENETIC RESTORATION OF MeCP2
All evidence indicates that RTT has an extremely subtle patho-
physiology compared to other severe neurodegenerative disorders.
Genetic intervention and pharmacological treatments have been
shown to rescue certain phenotypes of RTT, indicating that some
deﬁcits are reversible. Several genetic manipulation approaches
have been tested for the reversal of behavioral impairments in
RTTmouse models (see Table 2 for a summary of the major ﬁnd-
ings). One recent unbiased, high-content, small molecule screen
in primary cortical neurons derived from theAngelman syndrome
mousemodel revealed a possible new therapeutic avenue that may
be applicable to RTT (Huang et al., 2012). This study showed
inhibitors of topoisomerase I and II, enzymes that regulate DNA
supercoiling, could be used to unsilence the dormant paternal copy
of the Ube3a gene (the primary genetic cause of Angelman Syn-
drome) in several regions of the nervous system. The resulting
unsilencing lead to the expression of a functionally normal Ube3a
protein, the level of which remained elevated in a subset of spinal
cord neuronsweeks after drug treatment. These ﬁnding highlight a
remarkable potential for a short-term treatment that could lead to
long-term effects on gene expression and possible reestablishment
of proper neuronal UBE3A function. Whether a similar high-
throughput screen can identify compounds that can be used to
unsilence and reactivate X-inactivated copy of Mecp2 is an open
question and an area of active research by several laboratories.
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CONVERGENCE OF EVIDENCE FOR A SUBSET OF
NEURODEVELOPMENTAL DISORDERS
Rett syndrome, Fragile-X syndrome (FXS), and TSC are examples
of monogenic disorders that show compromised synaptic plastic-
ity (Tavazoie et al., 2005; Moretti et al., 2006; Talos et al., 2008).
Although these diseases have diverse genetic origin and pheno-
types, they share common intermediates in the signaling pathways
that will inﬂuence the availability of new proteins for functional
and structural changes at the synapse. It is widely accepted that
protein synthesis, including local protein synthesis at synapses,
is required for several forms of synaptic plasticity (Sutton and
Schuman, 2006). This local protein synthesis enables synapses
to control synaptic strength independently of the cell body via
rapid translation from pre-existing mRNAs and therefore, the
mechanisms and the signaling pathways regulating translation are
likely to be intimately involved in modulating synaptic strength
(Figure 1). The PI3K/Akt/mTOR axis, ERK, and PKC γ,ζ signaling
pathways have been shown to be heavily involved in controlling all
the steps of the protein synthesis process (Lin et al., 1994; Beretta
et al., 1996; Dufner et al., 1999; Hou and Klann, 2004) and are
dysregulated at different levels in RTT, FXS, and TSC (Inoki et al.,
2002;Manning et al., 2002;Gross et al., 2010; Ricciardi et al., 2011).
FXS gene product FMRP may play several roles not associ-
ated directly with protein translation like trafﬁcking and half-life
stability of mRNA, but its major function is to act as a brake of
protein translation by attaching to poly-ribosomes through ERK-
mediated phosphorylation signaling (Mazroui et al., 2002; Gal-
lagher et al., 2004;Qin et al., 2005). The FXSmousemodel, a knock
out of Fmr1 gene, is characterized by de-repression of protein
translation but interestingly also has elevated PI3K/Akt/mTOR
and ERK (Hou et al., 2006) activity levels through a negative feed-
back loop with PIKE (Gross et al., 2010; Sharma et al., 2010).
TSC1 and 2 gene products (Hamartin and Tuberin respectively)
form a complex that are more directly implicated in the pro-
tein synthesis pathway as a downstream target of PI3K that
in turn becomes activated upon the binding of growth factors
(e.g., IGF or BDNF). Activated PI3K leads to the recruitment
of PDK1 and the serine/threonine protein kinase Akt, and sub-
sequent phosphorylation/activation of Akt by PDK1. Activated
Akt negatively regulates TSC complex by directly phosphorylating
TSC2.
It is thus remarkable that although they work in opposite
directions (FXS and TSC by protein synthesis up-regulation and
RTT through down-regulation), all of these syndromes share at
least certain common signaling pathways and a pathophysiological
point of convergence in the synapse (Figure 1),where tight regula-
tion is necessary for proper function. This convergence opens up
the possibility that these three disorders and maybe other ASDs
FIGURE 1 |The four major molecular pathways activated by
tyrosine kinase receptor B (TrkB) and IGF-1 receptor (IGF-1R).
Phospholipase gamma (PLCγ) in orange, mitogen activated protein
kinase (MAPK)/extracellular signal-regulated kinase (ERK) in green,
Phosphatidylinositol-3 kinase (PI3K)/Akt in blue, and Janus kinase
(JAK)/signal transducer and activator of transcription (STAT) in yellow.
MAPK and PI3K are common transduction pathways for these two
receptors whereas PLCγ is only speciﬁc for TrkB and JAK/STAT for
IGF-1R. FMRP, although not directly involved in any signaling pathway
is represented to show its inﬂuence in the different stages of protein
synthesis: transcription, through mRNA stability control and
translation.
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(such as Angelman disorder with a disrupted protein synthesis
control caused by a defectiveUBE3A) have related biological foun-
dations which can be exploited in the design of new therapeutic
strategies (Auerbach et al., 2011).
NEW AVENUES IN RTT RESEARCH
Almost two decades of research on RTT has led to the develop-
ment of an intriguing story of how a single transcription factor
can play a crucial role in neuronal development, synaptic matu-
ration, and plasticity. Although the primary function of MeCP2
in normal brain development remains unclear, it is becoming
increasingly evident that there is a complex interplay of genes
and environment which results in the synaptic and circuit-level
defects in brain function. Restoration of MeCP2 expression in
three-week-old brain resulted in improvements in LTP and neuro-
anatomical parameters (Guy et al., 2007), illustrating that it is
possible to improve the symptoms of this neuropsychiatric dis-
order. Disease models using induced pluripotent stem cells (iPS)
from RTT patients’ ﬁbroblasts have opened up a new avenue of
drug discovery for therapeutic treatment of RTT (Kim et al., 2011;
Marchetto et al., 2011). Recent data also suggests that immune
system, whether it is adaptive (T cells) or innate (microglia),
profoundly impact normal brain function and plasticity (Derecki
et al., 2010; Graeber and Streit, 2010; Tremblay et al., 2011). There-
fore, bone marrow transplant from healthy animals into mutant
Mecp2 male animals is being investigated as an approach for
amelioration of RTT symptoms (Derecki et al., 2012). Interest-
ingly, several new functions of MeCP2 are only beginning to be
understood including their role in dynamic genome regulation in
neurons (Muotri et al., 2010).With the exciting new discoveries of
genome-editing techniques using zinc-ﬁnger nucleases, an inter-
esting new possibility would be to generate and use rat models to
study RTT. Future studies with cell-type speciﬁc manipulation
of MeCP2 to identify and examine the circuit-level contribu-
tions to function promise to elucidate further mechanisms of
disease progression and provide new potential therapeutic targets
for RTT.
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